PetMeds® Files Annual Report for Fiscal Year 2025
PetMed Express, Inc., commonly known as PetMeds, is making headlines as it releases crucial financial information following the end of its fiscal year. This prominent online pet pharmacy has recently filed its Annual Report on Form 10-K for the year that concluded on March 31, 2025, providing transparency to its investors and stakeholders.
Financial Overview and Key Figures
For the fiscal year 2025, PetMeds reported net sales amounting to $227.0 million. This figure, while substantial, fell short of the initially estimated range of $231.6 million to $233.6 million. Much of this differential can be attributed to a realignment in their accounting practices concerning promotional sales reimbursements, adjusting these figures from revenue to cost of sales. Importantly, this adjustment did not have any adverse impact on the company's net income.
Another notable aspect of the report is the net loss recorded, which reached $6.3 million. This loss exceeded prior expectations which ranged between $4.5 million and $5.0 million, primarily due to a $1.2 million non-cash impairment charge concerning intangible assets. Despite these financial challenges, PetMeds maintains a healthy cash position of $54.7 million with no debt obligations as of March 31, 2025.
Leadership's Commitment to Shareholders
Leslie C. G. Campbell, the Board Chair and Interim CEO of PetMeds, expressed gratitude towards shareholders for their continued patience during a tumultuous period. He emphasized that the submission of the 10-K allows the company to focus on operational enhancements and the strategic execution of its long-term value creation plans. Campbell reassured stakeholders that the company will prioritize delivering high-quality care to its customers, a hallmark of PetMeds’ nearly 30-year legacy in the digital pharmacy space.
Future Reporting Plans
Looking ahead, the company is committing to a more structured reporting schedule. PetMeds plans to file its Quarterly Report on Form 10-Q for the first quarter ending June 30, 2025, as soon as feasible. This will be followed by earnings announcements for subsequent quarters, including the second quarter ending September 30, 2025. The return to regular quarterly earnings calls is a notable goal, reinforcing efficient communication with investors.
About PetMed Express, Inc.
Founded in 1996, PetMeds remains a leader in the direct-to-consumer pet healthcare market. It serves as a trusted national online pharmacy, licensed across all states in the U.S., and is supported by expert pharmacists who are committed to enhancing pet wellness alongside veterinary professionals. Under the PETS brand family, PetMeds offers a wide array of pet health solutions, ranging from well-known and generic medications to OTC supplements and nutrition specifically designed for pets. The company's mission is deeply rooted in ensuring the health and longevity of pets, empowering pet owners to provide the best care for their beloved animals.
Frequently Asked Questions
What were the main financial highlights reported for fiscal 2025?
PetMeds reported net sales of $227.0 million and a net loss of $6.3 million, significantly influenced by accounting adjustments and an impairment charge.
How is PetMeds planning to enhance its reporting practices?
The company is committed to filing its Quarterly Report on Form 10-Q promptly and resuming regular quarterly earnings calls to ensure transparent communication with investors.
What does the future look like for PetMeds?
PetMeds aims to refine its operational execution and continue delivering trusted pet care solutions while focusing on long-term value creation for its stakeholders.
Who is the current CEO of PetMeds?
The current Board Chair and Interim CEO of PetMeds is Leslie C. G. Campbell, overseeing the company during this transitional phase.
How can investors get in touch with PetMeds?
Investors can contact PetMeds’ investor relations department through ICR, LLC, and reach out to Reed Anderson at (646) 277-1260 or via email.
